keyword
MENU ▼
Read by QxMD icon Read
search

Hepatic arterial infusion chemotherapy

keyword
https://www.readbyqxmd.com/read/28188368/complications-in-hepatic-arterial-infusion-chemotherapy-retrospective-comparison-of-catheter-tip-placement-in-the-right-left-hepatic-artery-vs-the-gastroduodenal-artery
#1
Rinpei Imamine, Toshiya Shibata, Ken Shinozuka, Kaori Togashi
PURPOSE: To compare the complication rates associated with hepatic arterial infusion chemotherapy (HAIC) for unresectable hepatocellular carcinoma (HCC) using two different catheter tip locations, the right/left hepatic artery (group 1) and the gastroduodenal artery (group 2). METHODS: Between April 2001 and March 2015, 88 patients (group 1, n = 36; group 2, n = 52) with unresectable HCC, underwent HAIC via a transfemorally placed infusion catheter. The incidence of complications related to catheter placement (including hepatic arterial occlusion, catheter dislocation, non-target embolization and port-catheter system infection) as well as catheter patency and patient survival were evaluated...
February 10, 2017: Surgery Today
https://www.readbyqxmd.com/read/28137738/reply-to-the-letter-to-the-editor-sorafenib-plus-hepatic-arterial-infusion-chemotherapy-with-cisplatin-vs-sorafenib-for-advanced-hepatocellular-carcinoma-randomized-phase-ii-trial-by-fornaro-et%C3%A2-al
#2
M Ikeda, S Shimizu, T Sato, M Morimoto, Y Kojima, Y Inaba, A Hagihara, M Kudo, S Nakamori, S Kaneko, R Sugimoto, T Tahara, T Ohmura, K Yasui, K Sato, H Ishii, J Furuse, T Okusaka
No abstract text is available yet for this article.
January 30, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28133129/-huge-hepatocellular-carcinoma-with-portal-vein-and-inferior-vena-cava-thrombi-treated-with-curative-liver-resection-and-perioperative-hepatic-arterial-infusion-chemotherapy-a-case-report
#3
Shinsaku Obara, Takeo Nomi, Ichirou Yamato, Daisuke Hokuto, Satoshi Yasuda, Chihiro Kawaguchi, Takahiro Yoshikawa, Masayuki Sho, Takatsugu Yamada, Takahiro Akahori, Shoichi Kinoshita, Minako Nagai, Hiromichi Kanehiro, Yoshiyuki Nakajima
The prognosis of hepatocellular carcinoma(HCC)with main portal vein(MPV)and/or the inferior vena cava(IVC)tumor thrombi is dismal. The management of HCC with severe tumor thrombus is complicated. In this study, we report a case of HCC with tumor thrombi in the MPV and IVC that was successfullytreated via liver resection and perioperative hepatic arterial infusion chemotherapy(HAI). A 68-year-old man was referred to our institution to treat huge HCC lesion in the right lobe of the liver. Abdominal computed tomography(CT)revealed a tumor(12 cm in diameter)in the right hepatic lobe and tumor thrombi in the MPV and IVC...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28058527/outcomes-of-a-phase-i-ii-trial-of-hepatic-arterial-infusion-of-oxaliplatin-combined-with-intravenous-5-fluorouracil-and-l-leucovorin-in-patients-with-unresectable-liver-metastases-from-colorectal-cancer-after-systemic-chemotherapy-failure
#4
Yozo Sato, Yoshitaka Inaba, Takashi Ura, Hideyuki Nishiofuku, Hidekazu Yamaura, Mina Kato, Daisuke Takahari, Toshihiro Tanaka, Kei Muro
PURPOSE: The purpose of this study was to assess hepatic arterial infusion (HAI) of oxaliplatin combined with intravenous 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in colorectal cancer (CRC) patients with systemic chemotherapy failure in a phase I/II trial. METHODS: CRC patients with unresectable liver metastases following standard systemic chemotherapy failure were eligible. A catheter-port system for HAI was placed using interventional radiology. In phase I, escalating doses of oxaliplatin for levels 1 and 2 were set at 50 and 100 mg/m(2), respectively, and were combined with fixed doses of intravenous 5-FU (200 mg/m(2) bolus and 2400 mg/m(2)/46-h continuous infusion) and l-LV (200 mg/m(2))...
January 6, 2017: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/28053537/comparison-of-intra-arterial-chemoembolization-with-and-without-radiotherapy-for-advanced-hepatocellular-carcinoma-with-portal-vein-tumor-thrombosis-a-meta-analysis
#5
Qianqian Zhao, Kunli Zhu, Jinbo Yue, Zhonghua Qi, Shumei Jiang, Xiaoqing Xu, Rui Feng, Renben Wang
PURPOSE: Numerous studies have tried to combine transarterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC) with radiotherapy (RT) for the treatment of hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT). However, the efficacy of TACE or HAIC combined with RT versus TACE or HAIC alone remains controversial. Thus, we performed a meta-analysis to compare the efficacy and safety of intra-arterial chemoembolization combined with RT versus intra-arterial chemoembolization alone for the treatment of HCC patients with PVTT...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28008623/relevance-of-cea-and-ldh-in-relation-to-kras-status-in-patients-with-unresectable-colorectal-liver-metastases
#6
Louise C Connell, Taryn M Boucher, Joanne F Chou, Marinela Capanu, Stephanie Maldonado, Nancy E Kemeny
BACKGROUND: While the significance of carcinoembryonic antigen (CEA), lactate dehydrogenase (LDH), and Kirsten rat sarcoma (KRAS) status as individual prognostic factors for patients with metastatic colorectal cancer has been addressed, the relationship and interdependence between these prognostic factors on survival is limited. METHODS: Patients with unresectable colorectal liver metastases with known KRAS status, and with baseline CEA and LDH levels who were treated with hepatic arterial infusion and systemic chemotherapy were identified...
December 23, 2016: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27995091/recent-advances-in-chemotherapy-and-surgery-for-colorectal-liver-metastases
#7
REVIEW
Guillaume Passot, Olivier Soubrane, Felice Giuliante, Giuseppe Zimmitti, Diane Goéré, Suguru Yamashita, Jean-Nicolas Vauthey
BACKGROUND: The liver is the most common site of metastases for colorectal cancer, and combined resection with systemic chemotherapy is the most effective strategy for survival. The aim of this article is to provide a comprehensive summary on four hot topics related to chemotherapy and surgery for colorectal liver metastases (CLM), namely: (1) chemotherapy-related liver injuries: prediction and impact, (2) surgery for initially unresectable CLM, (3) the emerging role of RAS mutations, and (4) the role of hepatic arterial infusion of chemotherapy (HAIC)...
November 2016: Liver Cancer
https://www.readbyqxmd.com/read/27993799/moving-beyond-sorafenib-alone-in-advanced-hepatocellular-carcinoma-is-hepatic-arterial-infusion-chemotherapy-the-best-option
#8
L Fornaro, C Vivaldi, G Lorenzoni, G Masi, I Bargellini
No abstract text is available yet for this article.
December 19, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27993355/intra-arterial-therapies-for-colorectal-cancer-liver-metastases-radioembolization-excluded
#9
REVIEW
Thierry de Baere, Lambros Tselikas, Valérie Boige, Michel Ducreux, David Malka, Diane Goéré, Eléonore Benahim, Frédéric Deschamps
During the past 20 years, advances in systemic therapies have improved overall survival of patients with Colorectal cancer Liver metastases (CRLM) from 6 to 24 months. By reaching CRLM via their preferential arterial vascularization, hepatic arterial infusion of chemotherapy (HAIC) has demonstrated improvement in response rate and deepness of response. Improvement in deepness of response is potentially helpful to convert no surgical patient to surgery. Recent HAIC regimens, including HAIC-FUDR plus systemic oxaliplatin/irinotecan, or HAIC-oxaliplatin plus systemic 5FU and cetuximab yielded a 92% and 90% response rate respectively, and conversion to R0 surgery in 47% and 42% of patients, respectively...
December 16, 2016: Bulletin du Cancer
https://www.readbyqxmd.com/read/27870679/new-developments-in-interventional-oncology-liver-metastases-from-colorectal-cancer
#10
Joseph R Kallini, Ahmed Gabr, Nadine Abouchaleh, Rehan Ali, Ahsun Riaz, Robert J Lewandowski, Riad Salem
Colorectal cancer is the third leading cause of cancer death in the United States. Although hepatic excision is the first-line treatment for colorectal liver metastasis (CRLM), few patients are candidates. Locoregional therapy (LRT) encompasses minimally invasive techniques practiced by interventional radiology. These include ablative treatments (radiofrequency ablation, microwave ablation, and cryosurgical ablation) and transcatheter intra-arterial therapy (hepatic arterial infusion chemotherapy, transarterial "bland" embolization, transarterial chemoembolization, and radioembolization with yttrium 90)...
November 2016: Cancer Journal
https://www.readbyqxmd.com/read/27820684/phase-ii-study-of-hepatic-arterial-infusion-chemotherapy-with-oxaliplatin-and-5-fluorouracil-for-advanced-perihilar-cholangiocarcinoma
#11
Xiaodong Wang, Jungang Hu, Guang Cao, Xu Zhu, Yong Cui, Xinqiang Ji, Xuan Li, Renjie Yang, Hui Chen, Haifeng Xu, Peng Liu, Jian Li, Jie Li, Chunyi Hao, Baocai Xing, Lin Shen
Purpose To evaluate the efficacy and safety of hepatic arterial infusion (HAI) of oxaliplatin and 5-fluorouracil for advanced perihilar cholangiocarcinoma (PCC) in this prospective phase II study. Materials and Methods The protocol was approved by the local ethics committee, and all patients gave informed consent. Patients with nonresectable PCC were included in a prospective, open phase II study investigating HAI through interventionally implanted port catheters. HAI consisted of infusions of oxaliplatin 40 mg/m(2) for 2 hours, followed by 5-fluorouracil 800 mg/m(2) for 22 hours on days 1-3 every 3-4 weeks...
November 7, 2016: Radiology
https://www.readbyqxmd.com/read/27768923/early-tumour-response-as-a-survival-predictor-in-previously-treated-patients-receiving-triplet-hepatic-artery-infusion-and-intravenous-cetuximab-for-unresectable-liver-metastases-from-wild-type-kras-colorectal-cancer
#12
Mohamed Bouchahda, Valérie Boige, Denis Smith, Abdoulaye Karaboué, Michel Ducreux, Mohamed Hebbar, Céline Lepère, Christian Focan, Rosine Guimbaud, Pasquale Innominato, Sameh Awad, Carlos Carvalho, Salvatore Tumolo, Stephanie Truant, Thierry De Baere, Denis Castaing, Philippe Rougier, Jean-François Morère, Julien Taieb, René Adam, Francis Lévi
BACKGROUND: Early tumour shrinkage has been associated with improved survival in patients receiving cetuximab-based systemic chemotherapy for liver metastases from colorectal cancer (LM-CRC). We tested this hypothesis for previously treated LM-CRC patients receiving cetuximab (500 mg/m(2)) and triplet hepatic artery infusion (HAI) within European trial OPTILIV. METHODS: Irinotecan (180 mg/m(2)), 5-fluorouracil (2800 mg/m(2)) and oxaliplatin (85 mg/m(2)) were given as chronomodulated or conventional delivery...
November 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/27750243/recent-trends-in-the-management-of-hepatocellular-carcinoma-with-special-emphasis-on-treatment-with-regorafenib-and-immune-checkpoint-inhibitors
#13
REVIEW
Masatoshi Kudo
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer deaths worldwide. Sonazoid-enhanced ultrasound and gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced MRI are the most important imaging modalities in diagnosing HCC. There are 2 non-contradictory HCC treatment algorithms in Japan. Hepatic arterial infusion chemotherapy plays an important role in the treatment of advanced HCC with main or branch portal vein invasion. Regorafenib, as a second-line systemic treatment, prolongs survival in patients with intermediate and advanced HCC who progressed on sorafenib...
2016: Digestive Diseases
https://www.readbyqxmd.com/read/27733753/unresectable-liver-metastases-in-colorectal-cancer-review-of-current-strategies
#14
Benjamin Sueur, Olivier Pellerin, Thibault Voron, Anne L Pointet, Julien Taieb, Simon Pernot
The objective of the treatment of colorectal cancer patients with unresectable liver metastases should be clearly defined at the outset. Potentially resectable patients should be distinguished from clearly unresectable patients. In defining resectability, it is important to take into account both anatomic characteristics and patient characteristic (comorbidities, symptoms, age). According to this evaluation, treatment should be tailored to each patient. The most widely accepted standard is doublet cytotoxic regimen plus biotherapy (anti-EGFR or anti-VEGF antibodies according to RAS status, but some patients could benefit from an intensified regimen, as triplet chemotherapy ± bevacizumab, or intraarterial treatments (hepatic arterial infusion, radioembolization or chemoembolization), in order to allow resectability...
December 2016: Minerva Chirurgica
https://www.readbyqxmd.com/read/27713643/postoperative-prophylactic-hepatic-arterial-infusion-chemotherapy-for-stage-iii-colorectal-cancer-a-retrospective-study
#15
Yao Wang, Xin Rong Sun, Wen Ming Feng, Ying Bao, Yin Yuan Zheng
BACKGROUND: Radical resection is the main treatment for colorectal cancer (CRC), but metastasis or recurrence is common in which liver metastasis accounted for 83% of the cases. Therefore, the prognosis of patients with advanced CRC may be improved if liver metastasis is prevented. This study aims to investigate the efficacy of hepatic arterial infusion chemotherapy (HAIC) on liver metastases of stage III CRC patients after curative resection. METHODS: Between 2002 and 2008, 287 stage III CRC patients who had undergone radical resection were included in this study...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27586890/advanced-hepatocellular-carcinoma-with-hepatic-vein-tumor-thrombosis-and-renal-dysfunction-after-hepatic-arterial-infusion-chemotherapy-effectively-treated-by-liver-resection-with-active-veno-venous-bypass-report-of-a-case
#16
Atene Itoh, Hiroshi Sadamori, Kazuhisa Yabushita, Kazuteru Monden, Masashi Tatsukawa, Masayoshi Hioki, Tsuyoshi Hyodo, Kunihiro Omonishi, Toru Ueki, Satoshi Ohno, Kohsaku Sakaguchi, Norihisa Takakura
BACKGROUND: Hepatocellular carcinoma (HCC) patients with hepatic vein tumor thrombosis (HVTT) extending to the inferior vena cava (IVC) have an extremely poor prognosis. Here we report a case of HCC with HVTT and renal dysfunction after hepatic arterial infusion chemotherapy (HAIC) successfully treated by liver resection and active veno-venous bypass. CASE PRESENTATION: A 77-year-old man was diagnosed to have a large HCC with intrahepatic metastases and HVTT extending to the IVC...
2016: BMC Cancer
https://www.readbyqxmd.com/read/27573564/sorafenib-plus-hepatic-arterial-infusion-chemotherapy-with-cisplatin-versus-sorafenib-for-advanced-hepatocellular-carcinoma-randomized-phase-ii-trial
#17
M Ikeda, S Shimizu, T Sato, M Morimoto, Y Kojima, Y Inaba, A Hagihara, M Kudo, S Nakamori, S Kaneko, R Sugimoto, T Tahara, T Ohmura, K Yasui, K Sato, H Ishii, J Furuse, T Okusaka
BACKGROUND: Sorafenib (Sor) is acknowledged as a standard therapy for advanced hepatocellular carcinoma (HCC). This trial was conducted to evaluate the effect of addition of hepatic arterial infusion chemotherapy with cisplatin (SorCDDP) to Sor for the treatment of advanced HCC. PATIENTS AND METHODS: We conducted a multicenter open-labeled randomized phase II trial in chemo-naïve patients with advanced HCC with Child-Pugh scores of 5-7. Eligible patients were randomly assigned 2:1 to receive SorCDDP (sorafenib: 400 mg bid; cisplatin: 65 mg/m(2), day 1, every 4-6 weeks) or Sor (400 mg bid)...
November 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27566258/response-rates-of-hepatic-arterial-infusion-pump-therapy-in-patients-with-metastatic-colorectal-cancer-liver-metastases-refractory-to-all-standard-chemotherapies
#18
Andrea Cercek, Taryn M Boucher, Jill S Gluskin, Ariel Aguiló, Joanne F Chou, Louise C Connell, Marinela Capanu, Diane Reidy-Lagunes, Michael D'Angelica, Nancy E Kemeny
BACKGROUND AND OBJECTIVES: To evaluate the role of hepatic arterial infusion (HAI) in patients with metastatic colorectal cancer (mCRC) liver metastases (LM) refractory to oxaliplatin, irinotecan, and fluorouracil-based treatments. METHODS: A search identified patients with mCRC treated after tumor progression on at least three standard systemic therapies. RESULTS: One hundred and ten patients met criteria for inclusion (i.e., progression on at least three standard agents)...
November 2016: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27529576/robotic-assisted-placement-of-hepatic-artery-infusion-pump-is-a-safe-and-feasible-approach
#19
Mashaal Dhir, Mazen S Zenati, James C Padussis, Heather L Jones, Samantha Perkins, Amber K Clifford, Jennifer Steve, Melissa E Hogg, Haroon A Choudry, Matthew P Holtzman, Herbert J Zeh, James F Pingpank, David L Bartlett, Amer H Zureikat
BACKGROUND: Hepatic artery infusion (HAI) chemotherapy can be combined with systemic chemotherapy for the treatment of isolated unresectable colorectal liver metastases (IU-CRLM) and intrahepatic cholangiocarcinoma (U-ICC). However, HAI pump placement requires a major laparotomy that may be associated with morbidity. We hypothesized that the computer-assisted robotic platform would be well suited for this procedure and report the first single institutional case series of robotic assisted HAI pump placement for primary and secondary malignancies of the liver...
September 2016: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27522991/early-decreases-in-%C3%AE-fetoprotein-and-des-%C3%AE-carboxy-prothrombin-predict-the-antitumor-effects-of-hepatic-transarterial-infusion-chemotherapy-with-cisplatin-cddp-powder-in-patients-with-advanced-hepatocellular-carcinoma
#20
Takeshi Hatanaka, Satoru Kakizaki, Yasushi Shimada, Daichi Takizawa, Kenji Katakai, Yuichi Yamazaki, Ken Sato, Motoyasu Kusano, Masanobu Yamada
Objective We retrospectively investigated the relationship between the tumor response and serial changes in α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) during hepatic arterial infusion of a cisplatin powder formulation (CDDP powder) in patients with advanced hepatocellular carcinoma (HCC). Methods Seventy-six advanced HCC patients were analyzed. All HCC patients received high-concentration cisplatin (1.43 mg/mL) via the haptic artery at a dose of 65 mg/m(2). AFP and DCP were measured at baseline and four to eight weeks after treatment, and the antitumor responses were evaluated according to the response evaluation criteria in solid tumours (RECIST) criteria after one or two courses of treatment...
2016: Internal Medicine
keyword
keyword
84585
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"